Keyphrases
Anti-vascular Endothelial Growth Factor (anti-VEGF)
19%
Bevacizumab
53%
Bevacizumab Treatment
15%
Combination Therapy
19%
Glioblastoma
30%
Glioblastoma multiforme
37%
Human Glioblastoma
25%
Irinotecan
34%
MicroPET
18%
Orthotopic Model
25%
Overall Survival
15%
Prognostic Factors
15%
Quality of Life
16%
Treatment Response
17%
Xenograft
15%
Medicine and Dentistry
Bevacizumab
21%
Epidermal Growth Factor Receptor
15%
Fluorine-18
29%
Glioblastoma
87%
Irinotecan
21%
Neoplasm
29%
Polyethylene Terephthalate
15%
Treatment Response
18%
Vasculotropin
27%
Xenograft
20%
Pharmacology, Toxicology and Pharmaceutical Science
Bevacizumab
46%
Biological Marker
16%
Epidermal Growth Factor Receptor
15%
Fluorine 18
17%
Glioblastoma
100%
Irinotecan
21%
Neoplasm
24%
Overall Survival
18%
Vasculotropin
27%